Literature DB >> 21918895

Dual biological effects of the cytokines interleukin-10 and interferon-γ.

Cailin Moira Wilke1, Shuang Wei, Lin Wang, Ilona Kryczek, John Kao, Weiping Zou.   

Abstract

It is generally thought that each cytokine exerts either immune stimulatory (inflammatory) or immune inhibitory (antiinflammatory or regulatory) biological activities. However, multiple cytokines can enact both inhibitory and stimulatory effects on the immune system. Two of these cytokines are interleukin (IL)-10 and interferon-gamma (IFNγ). IL-10 has demonstrated antitumor immunity even though it has been known for years as an immunoregulatory protein. Generally perceived as an immune stimulatory cytokine, IFNγ can also induce inhibitory molecule expression including B7-H1 (PD-L1), indoleamine 2,3-dioxygenase (IDO), and arginase on multiple cell populations (dendritic cells, tumor cells, and vascular endothelial cells). In this review, we will summarize current knowledge of the dual roles of both of these cytokines and stress the previously underappreciated stimulatory role of IL-10 and inhibitory role of IFNγ in the context of malignancy. Our progressive understanding of the dual effects of these cytokines is important for dissecting cytokine-associated pathology and provides new avenues for developing effective immune therapy against human diseases, including cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21918895     DOI: 10.1007/s00262-011-1104-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  50 in total

Review 1.  Cytokines that target immune killer cells against tumors.

Authors:  Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2020-06-10       Impact factor: 11.530

Review 2.  Programmed death-1 checkpoint blockade in acute myeloid leukemia.

Authors:  Alison Sehgal; Theresa L Whiteside; Michael Boyiadzis
Journal:  Expert Opin Biol Ther       Date:  2015-06-03       Impact factor: 4.388

3.  Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status.

Authors:  Jaemoon Koh; Heounjeong Go; Bhumsuk Keam; Moon-Young Kim; Soo Jeong Nam; Tae Min Kim; Se-Hoon Lee; Hye Sook Min; Young Tae Kim; Dong-Wan Kim; Yoon Kyung Jeon; Doo Hyun Chung
Journal:  Mod Pathol       Date:  2015-07-17       Impact factor: 7.842

4.  The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy.

Authors:  Yuan Wei; Qiyi Zhao; Zhiliang Gao; Xiang-Ming Lao; Wei-Ming Lin; Dong-Ping Chen; Ming Mu; Chun-Xiang Huang; Zheng-Yu Liu; Bo Li; Limin Zheng; Dong-Ming Kuang
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 14.808

Review 5.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

6.  Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study.

Authors:  Salvinia Mletzko; David J Pinato; Rebecca C Robey; Alessia Dalla Pria; Peter Benson; Nesrina Imami; Mark Bower
Journal:  Oncoimmunology       Date:  2017-04-07       Impact factor: 8.110

Review 7.  The role of the immune system in neurofibromatosis type 1-associated nervous system tumors.

Authors:  Souvik Karmakar; Karlyne M Reilly
Journal:  CNS Oncol       Date:  2016-12-21

8.  Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes.

Authors:  Pierre L Triozzi; Lynn Schoenfield; Thomas Plesec; Yogen Saunthararajah; Raymond R Tubbs; Arun D Singh
Journal:  Oncoimmunology       Date:  2014-10-31       Impact factor: 8.110

9.  IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4+ T cells and promoting CTL persistence in a murine model of plasmacytoma.

Authors:  Lixin Wang; Jin-Qing Liu; Fatemeh Talebian; Zhenzhen Liu; Li Yu; Xue-Feng Bai
Journal:  Oncoimmunology       Date:  2015-05-13       Impact factor: 8.110

Review 10.  Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.

Authors:  Kim A Reiss; Patrick M Forde; Julie R Brahmer
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.